Skip to main content
Equibles

J.R. DeVita

Head of Investor Relations

Nuvation Bio Inc. (NUVB)

Equibles does not estimate personal net worth.

Get an email with a short summary when Nuvation Bio Inc. publishes a filing, an earnings call transcript or a press release.

Get NUVB alerts

About J.R. DeVita

J.R. DeVita is recorded as Head of Investor Relations at Nuvation Bio Inc. (NUVB). J.R. DeVita has spoken on 5 earnings calls and 1 other investor event across 1 company, most recently for Nuvation Bio Inc. on August 6, 2026. Nuvation Bio Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nuvation Bio Inc. includes David Hung (CEO and Board Member), Moses Makunje (CFO and Chief Accounting Officer), Philippe Sauvage (CFO) and 7 others.

J.R. DeVita on recent calls

“Earlier today, we issued a press release summarizing our financial results for the quarter ending June 30, 2026, and provided a business update.”
Head of Investor Relations, Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 ·
“Earlier today, we issued a press release summarizing our financial results for the quarter ending March 31, 2026, and providing a business update.”
Head of Investor Relations, Nuvation Bio Inc. Q1 FY2026 Earnings Call ·
“Earlier today, we released financial results for the quarter and year ending December 31st, 2025, and provided a business update.”
Head of Investor Relations, Nuvation Bio Inc. Q4 FY2025 Earnings Call ·
“Earlier today, we released financial results for the quarter ending September 30th, 2025, and provided a business update. The press release is available on the Investor Section of our website at NewvationBio.com, and a recording of this conference call will also be available on our website following its completion.”
Head of Investor Relations, Nuvation Bio Inc. Q3 FY2025 Earnings Call ·
“We recently issued a press release announcing the U.S. FDA approval of talotrexanib, now known under the branded name Ibtrozi in the United States. Ibtrozi is a next-generation oral tyrosine kinase inhibitor, or TKI, for advanced ROS1-positive non-small cell lung cancer, or NSCLC.”
Head of Investor Relations, Nuvation Bio FDA Approval Conference Call ·

Affiliation history

Company network

Leadership on record at Nuvation Bio Inc.

Recent activity